Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

VIA Pharmaceuticals stock

VIAP
US92554T1034

Price

0.00
Today +/-
+0
Today %
+0 %
P

VIA Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the VIA Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the VIA Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the VIA Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze VIA Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

VIA Pharmaceuticals Stock Price History

DateVIA Pharmaceuticals Price
8/30/20240.00 undefined
7/31/20240.00 undefined

VIA Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into VIA Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by VIA Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects VIA Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of VIA Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into VIA Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing VIA Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on VIA Pharmaceuticals’s growth potential.

VIA Pharmaceuticals Revenue, EBIT and net profit per share

DateVIA Pharmaceuticals RevenueVIA Pharmaceuticals EBITVIA Pharmaceuticals Net Income
2011e-9,291.51 TT undefined0 undefined0 undefined
20100 undefined-5.91 M undefined-9.6 M undefined
20090 undefined-13.25 M undefined-20.98 M undefined
20080 undefined-20.46 M undefined-20.27 M undefined
20070 undefined-18.53 M undefined-21.84 M undefined
20060 undefined-8.22 M undefined-8.63 M undefined
200583,000 undefined-19.76 M undefined-19.74 M undefined
200480,000 undefined-10.19 M undefined-10.38 M undefined
200340,000 undefined-11.12 M undefined-30.41 M undefined
20021.12 M undefined-11.62 M undefined-12.05 M undefined
2001300,000 undefined-11.86 M undefined-11.1 M undefined
2000160,000 undefined-8.62 M undefined-9.61 M undefined
1999120,000 undefined-3.41 M undefined-3.82 M undefined
1998190,000 undefined-2.21 M undefined-7.96 M undefined
1997190,000 undefined-300,000 undefined-300,000 undefined
19960 undefined-520,000 undefined-440,000 undefined

VIA Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (k)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1996199719981999200020012002200320042005200620072008200920102011e
0000001,00000000000-9.29 TT
----------------
------100.00---------
0000001,000000000000
00-2-3-8-11-11-11-10-19-8-18-20-13-50
-------1,100.00---------
00-7-3-9-11-12-30-10-19-8-21-20-20-90
----57.14200.0022.229.09150.00-66.6790.00-57.89162.50-4.76--55.00-
0.851.041.141.5433.33.419.213.1416.950.449.7319.6119.9420.40
----------------
Details

Keystats

ⓘ

Revenue and Growth

The VIA Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the VIA Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19971998199920002001200220032004200520062007200820092010
                           
0.070.320.9221.3616.364.918.9124.4930.963.3423.14.072.190.08
035011010540704060000000
00000000000000
00000000000000
02010200280350650650443111953604155.36360.32
0.070.691.0421.5717.185.339.625.231.413.4524.054.672.350.44
00.380.572.192.352.620.190.090.080.180.340.290.170.02
00000000000000
00000000000000
0000000002626000
00000000000000
00.030.210.691.582.670.750.720.020.070.070.040.040.03
00.410.782.883.935.290.940.810.110.280.430.330.210.06
0.071.11.8224.4521.1110.6210.5426.0131.513.7324.4852.560.5
                           
1010102020010202110202120.6520.56
0.756.7611.6141.9350.751.3878.1797.29116.5112.6260.8862.1770.3972.69
-0.74-8.71-12.52-22.13-33.23-45.28-75.69-86.07-105.81-18.52-40.35-60.63-81.6-91.21
0000000001317000
000360290000000000
0.02-1.94-0.920.1817.786.12.4911.2410.72-5.8720.561.57-11.2-18.5
0.070.710.40.450.611.410.381.260.540.150.750.750.710.79
00.260.160.420.51.150.880.473.491.443.182.652.231.4
0000001.210.820.080000.792.79
0000000008001014
09904035068071038030032000
0.071.960.61.221.793.272.852.584.119.593.933.4113.7218.99
000.050.610.70.514.3211.4116.1200000
00000000000000
01.072.082.430.830.750.880.80.720.0100.030.040.01
01.072.133.041.531.265.212.2116.830.0100.030.040.01
0.073.032.734.263.324.538.0514.7920.959.63.933.4413.7519
0.091.091.8324.4421.110.6310.5426.0331.673.7324.552.560.5
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of VIA Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand VIA Pharmaceuticals's financial health and stability.

Assets

VIA Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that VIA Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of VIA Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into VIA Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199619971998199920002001200220032004200520062007200820092010
00-7-3-9-11-12-30-10-19-8-21-20-20-9
000000000000000
000000000000000
00000-1,0000001,00001,000000
0060211210000182
000000000000000
000000000000000
000-3-6-10-9-7-9-18-8-18-18-11-6
0000-10-100000000
0000-17174-24-4010000
0000-15294-24-4010000
000000000000000
00100001741140104
0000020101818023000
0004286011252311280104
0004274000000000
000000000000000
00004-2-18-81219-19-1-2
-0.25-0.25-0.7-3.98-8.42-11.6-10.83-7.67-9.85-18.18-8.31-19.21-19.03-11.88-6.11
000000000000000

VIA Pharmaceuticals stock margins

The VIA Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of VIA Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for VIA Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the VIA Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the VIA Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the VIA Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the VIA Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the VIA Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the VIA Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the VIA Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

VIA Pharmaceuticals Margin History

VIA Pharmaceuticals Gross marginVIA Pharmaceuticals Profit marginVIA Pharmaceuticals EBIT marginVIA Pharmaceuticals Profit margin
2011e100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %-23,810.84 %-23,778.31 %
2004100 %-12,737.5 %-12,975 %
2003100 %-27,800 %-76,025 %
2002100 %-1,037.5 %-1,075.89 %
2001100 %-3,953.33 %-3,700 %
2000100 %-5,387.5 %-6,006.25 %
1999100 %-2,841.67 %-3,183.33 %
1998100 %-1,163.16 %-4,189.47 %
1997100 %-157.89 %-157.89 %
1996100 %0 %0 %

VIA Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The VIA Pharmaceuticals earnings per share therefore indicates how much revenue VIA Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue VIA Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates VIA Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of VIA Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating VIA Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

VIA Pharmaceuticals Revenue, EBIT and net profit per share

DateVIA Pharmaceuticals Sales per ShareVIA Pharmaceuticals EBIT per shareVIA Pharmaceuticals Earnings per Share
2011e-451.92 B undefined0 undefined0 undefined
20100 undefined-0.29 undefined-0.47 undefined
20090 undefined-0.66 undefined-1.05 undefined
20080 undefined-1.04 undefined-1.03 undefined
20070 undefined-1.9 undefined-2.24 undefined
20060 undefined-18.88 undefined-19.8 undefined
20050 undefined-1.17 undefined-1.16 undefined
20040.01 undefined-0.78 undefined-0.79 undefined
20030 undefined-1.21 undefined-3.31 undefined
20020.33 undefined-3.41 undefined-3.53 undefined
20010.09 undefined-3.59 undefined-3.36 undefined
20000.05 undefined-2.87 undefined-3.2 undefined
19990.08 undefined-2.21 undefined-2.48 undefined
19980.17 undefined-1.94 undefined-6.98 undefined
19970.18 undefined-0.29 undefined-0.29 undefined
19960 undefined-0.61 undefined-0.52 undefined

VIA Pharmaceuticals business model

VIA Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company was founded in 1999 in San Francisco. The vision of VIA Pharmaceuticals from the beginning was to develop more innovative therapies for the treatment of cardiovascular diseases that are more effective and have fewer side effects compared to existing treatment options. The company focuses on the discovery and exploration of new active substances and technologies that target the causes of cardiovascular diseases. VIA Pharmaceuticals' business model is based on collaboration with other biopharmaceutical companies and research institutes. For example, the company collaborates with the Cleveland Clinic and the University of California to advance the development of new drugs. Collaboration with investors and financial institutions also plays an important role in VIA Pharmaceuticals' business model. The various divisions of VIA Pharmaceuticals specialize in the treatment of cardiovascular diseases. In particular, drugs for the treatment of atherosclerosis, one of the main causes of cardiovascular diseases, are being developed. VIA Pharmaceuticals' research focuses on reducing inflammation and blood lipids. The products of VIA Pharmaceuticals are currently still in clinical development. One of the most promising products of the company is VIA-2291, a drug for the treatment of atherosclerosis. The drug specifically targets inflammation in blood vessels, reducing the risk of plaques and thrombosis. VIA-2291 has already shown promising results in clinical trials and is currently in phase 3 of clinical development. Other products of VIA Pharmaceuticals are in various stages of clinical development. Overall, VIA Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company relies on collaboration with other research institutes and biotech companies. The products of VIA Pharmaceuticals are currently still in clinical development but show promising results and could contribute to making the treatment of cardiovascular diseases more effective and with fewer side effects in the future. VIA Pharmaceuticals is one of the most popular companies on Eulerpool.com.

VIA Pharmaceuticals SWOT Analysis

Strengths

VIA Pharmaceuticals Inc possesses several key strengths that contribute to its market position and growth potential:

  • Strong and experienced management team, providing strategic direction and expertise in the pharmaceutical industry.
  • Robust pipeline of innovative drugs, offering potential for revenue diversification and expansion.
  • Focus on cardiovascular diseases, which represent a significant market opportunity with high demand.
  • Access to advanced research and development capabilities, facilitating the discovery of novel therapeutic solutions.
  • Established partnerships and collaborations with leading academic institutions and industry players, enhancing research capabilities and market reach.

Weaknesses

Despite its strengths, VIA Pharmaceuticals Inc also faces certain weaknesses that need to be addressed:

  • Limited financial resources, which may restrict the company's ability to fully capitalize on its drug pipeline and research efforts.
  • Dependence on a few key products, making the company vulnerable to market fluctuations and competition.
  • Relatively small scale of operations compared to larger pharmaceutical companies, potentially limiting the company's market share.
  • Possibility of regulatory hurdles and delays in obtaining necessary approvals for drug development and commercialization.

Opportunities

VIA Pharmaceuticals Inc can explore various opportunities to drive growth and maximize its market potential:

  • Expanding into international markets, leveraging the growing demand for cardiovascular drugs worldwide.
  • Investing in research and development to advance novel drug candidates, addressing unmet medical needs in the cardiovascular field.
  • Participating in strategic alliances and collaborations to access new markets, technologies, and resources.
  • Utilizing digital healthcare solutions to enhance patient care and treatment outcomes, fostering customer satisfaction and brand loyalty.

Threats

VIA Pharmaceuticals Inc faces certain threats that may impact its business and market position:

  • Intense competition from established pharmaceutical companies, necessitating constant innovation and differentiation.
  • Stringent regulatory requirements and standards, increasing time and costs for drug development and approval.
  • Economic downturns and fluctuations in healthcare spending, potentially affecting the demand for cardiovascular medications.
  • Emerging alternative therapies and treatment modalities that could disrupt the traditional pharmaceutical market.

VIA Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

VIA Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

VIA Pharmaceuticals shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue VIA Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates VIA Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of VIA Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating VIA Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

VIA Pharmaceuticals stock splits

In VIA Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for VIA Pharmaceuticals.

VIA Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2008-0.3 -0.25  (16.92 %)2008 Q3
6/30/2008-0.33 -0.27  (17.28 %)2008 Q2
3/31/2008-0.29 -0.3  (-5.04 %)2008 Q1
12/31/2007-0.34 -0.27  (20.98 %)2007 Q4
9/30/2007-0.23 -0.27  (-15.09 %)2007 Q3
1

Most common questions regarding VIA Pharmaceuticals

What values and corporate philosophy does VIA Pharmaceuticals represent?

VIA Pharmaceuticals Inc represents a strong commitment to innovation, integrity, and patient well-being. As a leading pharmaceutical company, VIA Pharmaceuticals Inc focuses on developing groundbreaking solutions for cardiovascular diseases. With a customer-centric approach, the company strives to improve the lives of individuals suffering from these ailments. VIA Pharmaceuticals Inc is dedicated to conducting extensive research, leveraging advanced technology, and collaborating with top experts in the field to discover novel therapies. By prioritizing the advancement of cardiovascular health, VIA Pharmaceuticals Inc aims to create a positive impact on global healthcare.

In which countries and regions is VIA Pharmaceuticals primarily present?

VIA Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company VIA Pharmaceuticals achieved?

VIA Pharmaceuticals Inc, a prominent player in the stock market, has achieved significant milestones throughout its journey. The company's accomplishments include successful completion of Phase 2 clinical trials for its lead product, VIA-2291, a novel cardiovascular drug. Additionally, VIA Pharmaceuticals Inc has attained positive results in the treatment of atherosclerosis and inflammatory diseases. With its unwavering commitment to research and development, VIA Pharmaceuticals Inc continues to pave the way for innovative solutions in the healthcare industry. Investors can rely on the company's dedication to achieving excellence and fostering growth in the stock market.

What is the history and background of the company VIA Pharmaceuticals?

VIA Pharmaceuticals Inc, founded in 1980, is a biotechnology company specializing in the research and development of medications to treat cardiovascular diseases. Headquartered in San Francisco, California, VIA Pharmaceuticals Inc focuses on developing innovative therapies that target inflammation and promote cardiovascular health. By leveraging its expertise in identifying inflammation biomarkers, the company aims to address the urgent need for improved treatments for diseases such as atherosclerosis, acute coronary syndrome, and peripheral arterial disease. With a dedicated team of researchers and scientists, VIA Pharmaceuticals Inc continues to make significant strides in the field of cardiovascular medicine, offering hope for better patient outcomes.

Who are the main competitors of VIA Pharmaceuticals in the market?

The main competitors of VIA Pharmaceuticals Inc in the market include companies such as Pfizer, Novartis, AstraZeneca, and Johnson & Johnson.

In which industries is VIA Pharmaceuticals primarily active?

VIA Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of VIA Pharmaceuticals?

The business model of VIA Pharmaceuticals Inc focuses on the development and commercialization of cardiovascular drug candidates. The company aims to address the unmet needs in the treatment of cardiovascular diseases, including atherosclerosis, by leveraging its expertise in cardiovascular biology and inflammation. VIA Pharmaceuticals Inc aims to identify and develop innovative therapies to reduce the risk of major adverse cardiovascular events, such as heart attacks and strokes. Through its research and development efforts, VIA Pharmaceuticals Inc strives to improve patient outcomes and quality of life by targeting the underlying mechanisms that contribute to cardiovascular disease progression.

What is the P/E ratio of VIA Pharmaceuticals 2024?

The P/E ratio cannot be calculated for VIA Pharmaceuticals at the moment.

What is the P/S ratio of VIA Pharmaceuticals 2024?

The P/S cannot be calculated for VIA Pharmaceuticals currently.

What is the AlleAktien quality score of VIA Pharmaceuticals?

The AlleAktien quality score for VIA Pharmaceuticals is 4/10.

What is the revenue of VIA Pharmaceuticals 2024?

The revenue cannot currently be calculated for VIA Pharmaceuticals.

How high is the profit of VIA Pharmaceuticals 2024?

The profit cannot currently be calculated for VIA Pharmaceuticals.

What is the business model of VIA Pharmaceuticals

VIA Pharmaceuticals Inc is a US-based biopharmaceutical company specializing in the research and development of new innovative drugs for the prevention and treatment of cardiovascular diseases. The company, founded in 2003 and headquartered in San Francisco, California, currently employs about 30 employees. The business model of VIA Pharmaceuticals Inc is based on the development and commercialization of drugs that reduce the risk of cardiovascular diseases or specifically treat them. The company collaborates closely with leading research institutions to develop innovative approaches and new drugs. VIA Pharmaceuticals Inc is divided into various business units, each specializing in different therapy areas. One of the most important areas is the development of drugs that reduce the risk of atherosclerosis, the hardening of blood vessels. The company uses the drug Via-2291, which inhibits the growth of atherosclerotic plaques, to reduce the risk of cardiovascular diseases such as heart attacks and strokes triggered by atherosclerosis. Another important business area is the development of therapeutics for the treatment of acute coronary syndromes (ACS). The company focuses on the discovery and development of drugs that inhibit the inflammatory process in the coronary arteries. VIA Pharmaceuticals Inc uses a combination of several drugs, which are being tested in a series of Phase 2 clinical trials. To drive the development and commercialization of its products, VIA Pharmaceuticals Inc collaborates closely with partners from the pharmaceutical and biotech industry. Particularly important partners in this context are the Biotechnology Industry Organization (BIO), the umbrella organization of the US biotechnology industry, and the American Heart Association (AHA). Collaborations and partnerships are intended to increase the reach of the company's products and technologies. In summary, VIA Pharmaceuticals Inc follows a business model that focuses on the research and development of innovative drugs for the prevention and treatment of cardiovascular diseases. With its technologies, products, and partnerships, the company is well positioned to serve the growing healthcare market and to take a leading role in the industry.

What is the VIA Pharmaceuticals dividend?

VIA Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does VIA Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for VIA Pharmaceuticals or the company does not pay out a dividend.

What is the VIA Pharmaceuticals ISIN?

The ISIN of VIA Pharmaceuticals is US92554T1034.

What is the VIA Pharmaceuticals ticker?

The ticker of VIA Pharmaceuticals is VIAP.

How much dividend does VIA Pharmaceuticals pay?

Over the past 12 months, VIA Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VIA Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of VIA Pharmaceuticals?

The current dividend yield of VIA Pharmaceuticals is .

When does VIA Pharmaceuticals pay dividends?

VIA Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VIA Pharmaceuticals?

VIA Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of VIA Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIA Pharmaceuticals located?

VIA Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIA Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIA Pharmaceuticals from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did VIA Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of VIA Pharmaceuticals in the year 2023?

In the year 2023, VIA Pharmaceuticals distributed 0 USD as dividends.

In which currency does VIA Pharmaceuticals pay out the dividend?

The dividends of VIA Pharmaceuticals are distributed in USD.

All fundamentals about VIA Pharmaceuticals

Our stock analysis for VIA Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIA Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.